SEATTLE, WA--(Marketwired - December 03, 2013) - Atossa Genetics, Inc. (NASDAQ: ATOS) announced today that two presentations will be made at the 2013 San Antonio Breast Cancer Symposium, December 10-14, 2013, in San Antonio, Texas, both involving technology that has been licensed to Atossa by A5 Genetics KFT, Corporation.
The presentations are:
Poster Session 3: Prognosis and Response Prediction: Biomarkers - Methods
P3-05-05: Classification using dynamic re-discovery of the strongest prognostic features in each analysis outperforms static gene expression signatures for prognostic prediction in breast cancer.
Györffy B, Karn T, Sztupinszki Z, Weltz B, Müller V, Pusztai L. Hungarian Academy of Sciences; J. W. Goethe-University; University of Hamburg; Yale Cancer Center.
Poster Session 4: Detection and Diagnosis
P4-03-03: Determination of lymph node status using the primary tumor's gene expression signature.
Gyorffy B, Sztupinszki Z, Weltz B, Chen S-C, Quay S. Research Laboratory of Pediatrics and Nephrology, Budapest, Hungary; Atossa Genetics, Inc. and the National Reference Laboratory for Breast Health, Seattle
"The San Antonio Breast Cancer Symposium's stated goal is to provide state-of-the-art information on the experimental biology, etiology, prevention, diagnosis, and therapy of breast cancer and premalignant breast disease, to an international audience of academic and private physicians and researchers," said Dr. Steven Quay, Chairman, CEO and President of Atossa. "We are pleased to be a part of this important meeting and to discuss our novel, patent-pending technology. The National Reference Laboratory for Breast Health, Inc., our CLIA-certified subsidiary, is currently validating the dynamic re-discovery algorithm for use in our transcriptome-based gene expression test of cancer recurrence. This laboratory developed test, which is currently under development, uses advanced microarray technologies to analyze the entire genetic transcriptome from core needle and excisional biopsies."
About Atossa Genetics
Atossa Genetics, Inc. is focused on proprietary products and services related to breast health through the commercialization of medical devices and, through its wholly-owned subsidiary, The National Reference Laboratory for Breast Health, Inc., the offering of laboratory services and tests. For additional information, please visit www.atossagenetics.com.
Forward-looking statements in this press release are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with actions by the FDA, the feedback from the pre-submission meeting and actions related thereto, the outcome or timing of regulatory clearances needed by Atossa to sell its products and services, responses to regulatory matters, Atossa's ability to continue to manufacture and sell its products, recalls of products, the efficacy of Atossa's products and services, the market demand for and acceptance of Atossa's products and services, performance of distributors, estimated future expenses and cash needs, and other risks detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.